Clinical Trials Logo

Clinical Trial Summary

The proposed study will examine the threshold for nicotine self-administration (NSA) using five different nicotine doses in young adult male and female non-dependent smokers (light and intermittent smokers or LITS). We propose a double-blind, placebo-controlled study that will enroll 195 individuals, targeting a total of 72 completers (36 male and 36 females). In each of the five experimental sessions, smokers will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.05, 0.1 and 0.2 mg/70 kg). The highest dose, 0.2 mg/70 kg, corresponds to nicotine delivered by about one or two puffs of a cigarette. At the beginning of each experimental session, smokers will sample the assigned both the nicotine dose for that experimental session, and the placebo (saline) dose, followed by the opportunity to choose between nicotine and placebo for a total of ten choices over a 150-minute period. The main outcomes will be threshold dose (the minimum dose of nicotine that is self-administered more than placebo) and the slope of dose-response for nicotine self-administration (changes in nicotine self-administration per unit change in nicotine dose). We will also collect measures of nicotine intake (cotinine), nicotine clearance (3-hydroxycotinine (3-HC) / cotinine), and self-report drug effects


Clinical Trial Description

Aim #1: To assess the threshold reinforcing dose and dose-effect curve for IV NSA at low doses in young adult LITS. Hypothesis #1A: The threshold reinforcing doses for IV NSA will be between 0.0125 to 0.1 mg/70 kg. Hypothesis #1B: The dose-effect curve for NSA will differ between males and females with relatively flat curve in female smokers. Aim #2: To assess the threshold and dose-effect curve for the positive and negative/aversive subjective effects of IV nicotine at low doses and its relationship to nicotine reinforcement. Hypothesis #2 A: The threshold for the positive effects will be between 0.0125 to 0.1 mg/70 kg, for the negative/aversive effect it will be ≥ 0.1 mg/70 kg. Hypothesis #2B: Nicotine reinforcement will be positively correlated with the positive and negatively correlated with the negative/aversive subjective effects of IV nicotine. Exploratory Aims: To examine the influence of nicotine clearance rate on nicotine reinforcement threshold and dose-effect curve. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01495819
Study type Interventional
Source Yale University
Contact
Status Completed
Phase Early Phase 1
Start date January 4, 2017
Completion date March 31, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02643914 - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings N/A
Completed NCT02153749 - Effects of Brief Training on Craving Regulation N/A
Recruiting NCT05530577 - Effects of Semaglutide on Nicotine Intake Phase 2
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A
Completed NCT03694327 - Innovative Digital Therapeutic for Smoking Cessation N/A
Completed NCT01944423 - Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine Early Phase 1
Completed NCT01704573 - Nicotinic Receptor Levels After Stopping Smoking N/A
Active, not recruiting NCT01015170 - STOP Study: Effectiveness of Zyban in a Clinical Population Phase 4
Completed NCT03281629 - Circuitry-Guided Smoking Cessation in Schizophrenia N/A
Recruiting NCT06291584 - Effects of Exercises on Functional Capacity N/A
Withdrawn NCT06259630 - Nicotine Virtual Reality Conditioned Place Preference Phase 4
Completed NCT02624284 - tDCS Effects on Resisting Smoking: Dose Ranging Study N/A
Active, not recruiting NCT02837510 - Neural Mechanisms Associated With Risk of Smoking Relapse N/A
Completed NCT02656745 - Clinical Trial of Smoking Cessation Mobile Phone Program N/A
Completed NCT01062932 - Investigation of Cycloserine as a Smoking Cessation Treatment Phase 1
Completed NCT03069482 - Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness Phase 1
Completed NCT02870218 - Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use Phase 2
Terminated NCT01756053 - Effects of ABT-089 on Smoking Abstinence Symptoms and Reward Phase 2
Completed NCT01252966 - Cognitive Training for Nicotine Dependence N/A
Active, not recruiting NCT04946825 - Quit Smoking Study for People Who Use E-Cigarettes Phase 2